DE60202727D1 - Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie - Google Patents

Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie

Info

Publication number
DE60202727D1
DE60202727D1 DE60202727T DE60202727T DE60202727D1 DE 60202727 D1 DE60202727 D1 DE 60202727D1 DE 60202727 T DE60202727 T DE 60202727T DE 60202727 T DE60202727 T DE 60202727T DE 60202727 D1 DE60202727 D1 DE 60202727D1
Authority
DE
Germany
Prior art keywords
cardiac hypertrophy
inhibition
treatment
histone deacetylase
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60202727T
Other languages
English (en)
Other versions
DE60202727T2 (de
Inventor
Michael R Bristow
Carlin Long
Timothy A Mckinsey
Eric N Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Colorado
Original Assignee
University of Texas System
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Colorado filed Critical University of Texas System
Application granted granted Critical
Publication of DE60202727D1 publication Critical patent/DE60202727D1/de
Publication of DE60202727T2 publication Critical patent/DE60202727T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60202727T 2001-09-27 2002-09-27 Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie Expired - Lifetime DE60202727T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32531101P 2001-09-27 2001-09-27
US325311P 2001-09-27
US33404101P 2001-10-31 2001-10-31
US334041P 2001-10-31

Publications (2)

Publication Number Publication Date
DE60202727D1 true DE60202727D1 (de) 2005-03-03
DE60202727T2 DE60202727T2 (de) 2005-12-29

Family

ID=26984878

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60202727T Expired - Lifetime DE60202727T2 (de) 2001-09-27 2002-09-27 Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie

Country Status (8)

Country Link
US (4) US6706686B2 (de)
EP (1) EP1297851B1 (de)
JP (2) JP2003238445A (de)
AT (1) ATE287731T1 (de)
DE (1) DE60202727T2 (de)
DK (1) DK1297851T3 (de)
ES (1) ES2236415T3 (de)
PT (1) PT1297851E (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137771A2 (de) * 1998-11-10 2001-10-04 The Board Of Regents, The University Of Texas System Verfahren zur vorbeugung von hypertrophie und versagen des herzens durch inhibierung des mefs-transkriptionsfaktors
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070104688A1 (en) * 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA05012619A (es) * 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
AU2004270150C1 (en) * 2003-08-29 2011-07-14 Merck Hdac Research, Llc Combination methods of treating cancer
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2555632A1 (en) * 2004-02-02 2005-08-18 Myogen, Inc. Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
CA2561954A1 (en) * 2004-04-05 2005-10-20 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
US9945840B2 (en) 2004-04-07 2018-04-17 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
EP2270196B1 (de) 2004-05-11 2016-04-20 Axiogenesis Ag Methoden zur Medikamentenaufspürung auf der Basis von in vitro differenzierten Zellen
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006088949A1 (en) 2005-02-14 2006-08-24 Miikana Therapeutics, Inc. Fused heterocyclic compounds useful as inhibitors of histone deacetylase
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
EP1896436A2 (de) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
KR20080032188A (ko) * 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
CA2614959A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
RU2008108909A (ru) * 2005-08-10 2009-09-20 Новартис АГ (CH) Способ применения ингибиторов деацетилазы
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
CA2630200A1 (en) * 2005-11-18 2007-05-24 Johannes Backs Uses for camki i and hdacs in the treatment of heart conditions
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
CA2647359A1 (en) * 2006-03-29 2007-11-08 Edward Via Virginia College Of Osteopathic Medicine Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
KR20080108156A (ko) * 2006-04-06 2008-12-11 노파르티스 아게 유기 화합물의 조합물
WO2007120839A2 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
CA2674309A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
WO2008140708A1 (en) * 2007-05-09 2008-11-20 The Trustees Of The University Of Pennsylvania Use of hdac inhibitors for treatment of cardiac rhythm disorders
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
US9226965B2 (en) * 2007-10-05 2016-01-05 U.S. Department Of Veterans Affairs Method and composition for treating heart failure
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
WO2010039697A2 (en) * 2008-09-30 2010-04-08 Gilead Sciences, Inc. Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
SG187032A1 (en) 2010-07-12 2013-02-28 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
EP2627316B1 (de) 2010-10-13 2019-03-27 Medivir AB Pharmazeutische formulierung für histondeacetylaseinhibitoren
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6060311A (en) * 1995-07-28 2000-05-09 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
ATE275956T1 (de) 1998-10-19 2004-10-15 Methylgene Inc Veränderung der dns methyltransferase durch kombinationstherapie
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
US6632628B1 (en) 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
AU7108400A (en) * 1999-09-03 2001-04-10 Salk Institute For Biological Studies, The Modulation of gene expression by modulating histone acetylation
WO2001017568A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
CA2383885A1 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
ATE320484T1 (de) 1999-12-08 2006-04-15 Axys Pharm Inc Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
AU2001298014A1 (en) 2000-03-24 2003-01-29 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
EP1170008A1 (de) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US20040077046A1 (en) 2000-12-20 2004-04-22 Dalia Cohen Histone deacetylase-related gene and protein
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
DK1297851T3 (da) 2005-05-30
US20030144340A1 (en) 2003-07-31
US6706686B2 (en) 2004-03-16
DE60202727T2 (de) 2005-12-29
JP2010001311A (ja) 2010-01-07
US20060069014A1 (en) 2006-03-30
ES2236415T3 (es) 2005-07-16
US20060025333A1 (en) 2006-02-02
US20040186049A1 (en) 2004-09-23
US6946441B2 (en) 2005-09-20
PT1297851E (pt) 2005-06-30
EP1297851A1 (de) 2003-04-02
EP1297851B1 (de) 2005-01-26
ATE287731T1 (de) 2005-02-15
JP2003238445A (ja) 2003-08-27

Similar Documents

Publication Publication Date Title
DE60202727D1 (de) Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie
DK1233958T3 (da) Hæmmere af histondeacetylase
DK1590340T3 (da) Histondeacetylase-inhibitorer
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
MXPA04002397A (es) Inhibidores de histona deacetilasa.
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
IN2005KO00312A (de)
PT1163208E (pt) Inibidores de caspase e as suas utilizacoes
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
ATE442141T1 (de) Verfahren zur behandlung von stoffwechselerkrankungen mit malonyl-coa- decarboxylase-hemmern
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
ATE410235T1 (de) Behandlung von ballastwasser
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks

Legal Events

Date Code Title Description
8364 No opposition during term of opposition